These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 27144829)
1. Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article. Safari M; Khoshnevisan A J Stem Cells; 2015; 10(4):271-85. PubMed ID: 27144829 [TBL] [Abstract][Full Text] [Related]
2. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Pistollato F; Abbadi S; Rampazzo E; Persano L; Della Puppa A; Frasson C; Sarto E; Scienza R; D'avella D; Basso G Stem Cells; 2010 May; 28(5):851-62. PubMed ID: 20309962 [TBL] [Abstract][Full Text] [Related]
3. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756 [TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Johannessen TC; Bjerkvig R Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898 [TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
6. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186 [TBL] [Abstract][Full Text] [Related]
7. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979 [TBL] [Abstract][Full Text] [Related]
8. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents. Szeliga M; Zgrzywa A; Obara-Michlewska M; Albrecht J J Neurochem; 2012 Nov; 123(3):428-36. PubMed ID: 22888977 [TBL] [Abstract][Full Text] [Related]
9. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436 [TBL] [Abstract][Full Text] [Related]
10. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma. Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111 [TBL] [Abstract][Full Text] [Related]
11. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016 [TBL] [Abstract][Full Text] [Related]
13. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma. William D; Walther M; Schneider B; Linnebacher M; Classen CF PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
15. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway. Huang H; Lin H; Zhang X; Li J Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504 [TBL] [Abstract][Full Text] [Related]
16. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279 [TBL] [Abstract][Full Text] [Related]
17. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246 [TBL] [Abstract][Full Text] [Related]
19. MGMT methylation in glioblastoma: tale of the tail. Shah N; Schroeder B; Cobbs C Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464 [No Abstract] [Full Text] [Related]
20. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]